445 related articles for article (PubMed ID: 23888997)
1. Mineralocorticoid receptor and cardiac arrhythmia.
Gravez B; Tarjus A; Jaisser F
Clin Exp Pharmacol Physiol; 2013 Dec; 40(12):910-5. PubMed ID: 23888997
[TBL] [Abstract][Full Text] [Related]
2. Mineralocorticoid receptor activation in myocardial infarction and failure: recent advances.
Galuppo P; Bauersachs J
Eur J Clin Invest; 2012 Oct; 42(10):1112-20. PubMed ID: 22536780
[TBL] [Abstract][Full Text] [Related]
3. RALES, EPHESUS and redox.
Funder JW
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):121-5. PubMed ID: 15860254
[TBL] [Abstract][Full Text] [Related]
4. Why are mineralocorticoid receptor antagonists cardioprotective?
Chai W; Danser AH
Naunyn Schmiedebergs Arch Pharmacol; 2006 Dec; 374(3):153-62. PubMed ID: 17075718
[TBL] [Abstract][Full Text] [Related]
5. Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies.
Pitt B
Mol Cell Endocrinol; 2004 Mar; 217(1-2):53-8. PubMed ID: 15134801
[TBL] [Abstract][Full Text] [Related]
6. Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease.
Pitt B; Stier CT; Rajagopalan S
J Renin Angiotensin Aldosterone Syst; 2003 Sep; 4(3):164-8. PubMed ID: 14608520
[TBL] [Abstract][Full Text] [Related]
7. Aldosterone and aldosterone antagonism in cardiovascular disease: focus on eplerenone (Inspra).
Stier CT; Koenig S; Lee DY; Chawla M; Frishman WH
Heart Dis; 2003; 5(2):102-18. PubMed ID: 12713678
[TBL] [Abstract][Full Text] [Related]
8. Aldosterone target organ protection by eplerenone.
Rudolph AE; Rocha R; McMahon EG
Mol Cell Endocrinol; 2004 Mar; 217(1-2):229-38. PubMed ID: 15134822
[TBL] [Abstract][Full Text] [Related]
9. Emerging cardiovascular indications of mineralocorticoid receptor antagonists.
Parviz Y; Iqbal J; Pitt B; Adlam D; Al-Mohammad A; Zannad F
Trends Endocrinol Metab; 2015 Apr; 26(4):201-11. PubMed ID: 25707577
[TBL] [Abstract][Full Text] [Related]
10. Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials.
Rossello X; Ariti C; Pocock SJ; Ferreira JP; Girerd N; McMurray JJV; Van Veldhuisen DJ; Pitt B; Zannad F
Clin Res Cardiol; 2019 May; 108(5):477-486. PubMed ID: 30264282
[TBL] [Abstract][Full Text] [Related]
11. Aldosterone, mineralocorticoid receptor, and heart failure.
Messaoudi S; Azibani F; Delcayre C; Jaisser F
Mol Cell Endocrinol; 2012 Mar; 350(2):266-72. PubMed ID: 21784127
[TBL] [Abstract][Full Text] [Related]
12. Blocking aldosterone in heart failure.
Shafiq MM; Miller AB
Ther Adv Cardiovasc Dis; 2009 Oct; 3(5):379-85. PubMed ID: 19661156
[TBL] [Abstract][Full Text] [Related]
13. Do diuretics and aldosterone receptor antagonists improve ventricular remodeling?
Pitt B
J Card Fail; 2002 Dec; 8(6 Suppl):S491-3. PubMed ID: 12555163
[TBL] [Abstract][Full Text] [Related]
14. Atrial natriuretic peptide locally counteracts the deleterious effects of cardiomyocyte mineralocorticoid receptor activation.
Nakagawa H; Oberwinkler H; Nikolaev VO; Gaßner B; Umbenhauer S; Wagner H; Saito Y; Baba HA; Frantz S; Kuhn M
Circ Heart Fail; 2014 Sep; 7(5):814-21. PubMed ID: 25027872
[TBL] [Abstract][Full Text] [Related]
15. Aldosterone receptor antagonists and cardiovascular disease: do we need a change of the guard?
Jewell CW; Watson LE; Mock J; Dostal DE
Cardiovasc Hematol Agents Med Chem; 2006 Apr; 4(2):129-53. PubMed ID: 16611048
[TBL] [Abstract][Full Text] [Related]
16. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
Iraqi W; Rossignol P; Angioi M; Fay R; Nuée J; Ketelslegers JM; Vincent J; Pitt B; Zannad F
Circulation; 2009 May; 119(18):2471-9. PubMed ID: 19398668
[TBL] [Abstract][Full Text] [Related]
17. Eplerenone-mediated regression of electrical activation delays and myocardial fibrosis in heart failure.
J Cardiovasc Electrophysiol; 2014 May; 25(5):556-577. PubMed ID: 24612029
[TBL] [Abstract][Full Text] [Related]
18. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Pitt B; Remme W; Zannad F; Neaton J; Martinez F; Roniker B; Bittman R; Hurley S; Kleiman J; Gatlin M;
N Engl J Med; 2003 Apr; 348(14):1309-21. PubMed ID: 12668699
[TBL] [Abstract][Full Text] [Related]
19. Mineralocorticoid receptors in the heart: lessons from cell-selective transgenic animals.
Young MJ; Rickard AJ
J Endocrinol; 2015 Jan; 224(1):R1-13. PubMed ID: 25335936
[TBL] [Abstract][Full Text] [Related]
20. Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor.
Rogerson FM; Yao Y; Smith BJ; Fuller PJ
Clin Exp Pharmacol Physiol; 2004 Oct; 31(10):704-9. PubMed ID: 15554912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
